(DAILYMAIL) — Regulators yesterday approved the first therapy in the western world that can correct errors in a person’s genetic code.
Europe has approved Glybera to be used against a rare inherited disorder which disrupts fat production in the body.
The treatment uses a virus to counteract LPLD, lipoprotein lipase deficiency, which can led to acute inflammation of the pancreas.
The illness affects around one or two people per million and sufferers have damaged copies of a gene which is essential for breaking down fats. The virus infects muscle cells with a copy of a healthy gene and a one-off treatment is effective.